de Commonwealth Equity Services Jazz Pharmaceuticals JAZZ Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 2.88 M | Vender |
11,939
-192
| -2% | -USD 42.1 k | ﹤0.01% | 1806 |
|
|
2026
Q1 | USD 2.29 M | Vender |
12,131
-756
| -6% | -USD 132 k | ﹤0.01% | 1891 |
|
|
2025
Q4 | USD 2.19 M | Comprar |
12,887
+769
| +6% | +USD 118 k | ﹤0.01% | 1892 |
|
|
2025
Q3 | USD 1.6 M | Comprar |
12,118
+810
| +7% | +USD 97.2 k | ﹤0.01% | 2201 |
|
|
2025
Q2 | USD 1.2 M | Vender |
11,308
-2,899
| -20% | -USD 315 k | ﹤0.01% | 2415 |
|
|
2025
Q1 | USD 1.76 M | Comprar |
14,207
+1,323
| +10% | +USD 173 k | ﹤0.01% | 1998 |
|
|
2024
Q4 | USD 1.59 M | Vender |
12,884
-784
| -6% | -USD 92.4 k | ﹤0.01% | 2036 |
|
|
2024
Q3 | USD 1.52 M | Comprar |
13,668
+146
| +1% | +USD 16 k | ﹤0.01% | 2022 |
|
|
2024
Q2 | USD 1.44 M | Comprar |
13,522
+364
| +3% | +USD 40 k | ﹤0.01% | 2005 |
|
|
2024
Q1 | USD 1.58 M | Comprar |
13,158
+2,318
| +21% | +USD 284 k | ﹤0.01% | 1927 |
|
|
2023
Q4 | USD 1.33 M | Comprar |
10,840
+767
| +8% | +USD 95.7 k | ﹤0.01% | 1969 |
|
|
2023
Q3 | USD 1.3 M | Comprar |
10,073
+962
| +11% | +USD 128 k | ﹤0.01% | 1891 |
|
|
2023
Q2 | USD 1.13 M | Comprar |
9,111
+47
| +0.5% | +USD 6.32 k | ﹤0.01% | 2008 |
|
|
2023
Q1 | USD 1.33 M | Vender |
9,064
-300
| -3% | -USD 44.4 k | ﹤0.01% | 1847 |
|
|
2022
Q4 | USD 1.49 M | Vender |
9,364
-96
| -1% | -USD 14.1 k | ﹤0.01% | 1688 |
|
|
2022
Q3 | USD 1.26 M | Vender |
9,460
-30
| -0.3% | -USD 4.56 k | ﹤0.01% | 1740 |
|
|
2022
Q2 | USD 1.48 M | Vender |
9,490
-677
| -7% | -USD 104 k | ﹤0.01% | 1608 |
|
|
2022
Q1 | USD 1.58 M | Comprar |
10,167
+447
| +5% | +USD 64.9 k | ﹤0.01% | 1647 |
|
|
2021
Q4 | USD 1.24 M | Vender |
9,720
-10,475
| -52% | -USD 1.38 M | ﹤0.01% | 1832 |
|
|
2021
Q3 | USD 2.63 M | Comprar |
20,195
+8,672
| +75% | +USD 1.31 M | 0.01% | 1265 |
|
|
2021
Q2 | USD 2.05 M | Comprar |
11,523
+7,397
| +179% | +USD 1.28 M | 0.01% | 1407 |
|
|
2021
Q1 | USD 678 k | Vender |
4,126
-10,523
| -72% | -USD 1.73 M | ﹤0.01% | 2082 |
|
|
2020
Q4 | USD 2.42 M | Comprar |
14,649
+11,559
| +374% | +USD 1.72 M | 0.01% | 1118 |
|
|
2020
Q3 | USD 440 k | Vender |
3,090
-354
| -10% | -USD 43.9 k | ﹤0.01% | 2058 |
|
|
2020
Q2 | USD 380 k | Vender |
3,444
-920
| -21% | -USD 102 k | ﹤0.01% | 2091 |
|
|
2020
Q1 | USD 435 k | Comprar |
4,364
+437
| +11% | +USD 56.5 k | ﹤0.01% | 1789 |
|
|
2019
Q4 | USD 586 k | Comprar |
3,927
+816
| +26% | +USD 111 k | ﹤0.01% | 1782 |
|
|
2019
Q3 | USD 398 k | Vender |
3,111
-227
| -7% | -USD 30.4 k | ﹤0.01% | 2001 |
|
|
2019
Q2 | USD 475 k | Comprar |
3,338
+92
| +3% | +USD 12.4 k | ﹤0.01% | 1842 |
|
|
2019
Q1 | USD 464 k | Comprar |
3,246
+290
| +10% | +USD 37.8 k | ﹤0.01% | 1800 |
|
|
2018
Q4 | USD 366 k | Vender |
2,956
-244
| -8% | -USD 36.2 k | ﹤0.01% | 1868 |
|
|
2018
Q3 | USD 538 k | Vender |
3,200
-309
| -9% | -USD 53.1 k | ﹤0.01% | 1749 |
|
|
2018
Q2 | USD 605 k | Comprar |
3,509
+226
| +7% | +USD 36.9 k | ﹤0.01% | 1618 |
|
|
2018
Q1 | USD 495 k | Vender |
3,283
-113
| -3% | -USD 16.6 k | ﹤0.01% | 1720 |
|
|
2017
Q4 | USD 457 k | Vender |
3,396
-723
| -18% | -USD 100 k | ﹤0.01% | 1752 |
|
|
2017
Q3 | USD 602 k | Vender |
4,119
-25
| -0.6% | -USD 3.78 k | ﹤0.01% | 1494 |
|
|
2017
Q2 | USD 644 k | Vender |
4,144
-1,500
| -27% | -USD 229 k | ﹤0.01% | 1402 |
|
|
2017
Q1 | USD 819 k | Vender |
5,644
-662
| -10% | -USD 86.2 k | 0.01% | 1223 |
|
|
2016
Q4 | USD 688 k | Comprar |
6,306
+358
| +6% | +USD 39.9 k | 0.01% | 1231 |
|
|
2016
Q3 | USD 723 k | Comprar |
5,948
+267
| +5% | +USD 36 k | 0.01% | 1167 |
|
|
2016
Q2 | USD 803 k | Comprar |
5,681
+230
| +4% | +USD 33.9 k | 0.01% | 1094 |
|
|
2016
Q1 | USD 712 k | Vender |
5,451
-92
| -2% | -USD 11.5 k | 0.01% | 1122 |
|
|
2015
Q4 | USD 779 k | Comprar |
5,543
+330
| +6% | +USD 45.7 k | 0.01% | 1057 |
|
|
2015
Q3 | USD 692 k | Comprar |
5,213
+712
| +16% | +USD 123 k | 0.01% | 1074 |
|
|
2015
Q2 | USD 792 k | Vender |
4,501
-120
| -3% | -USD 21.6 k | 0.01% | 1084 |
|
|
2015
Q1 | USD 798 k | Vender |
4,621
-279
| -6% | -USD 47.9 k | 0.01% | 1071 |
|
|
2014
Q4 | USD 802 k | Comprar |
4,900
+686
| +16% | +USD 114 k | 0.01% | 1012 |
|
|
2014
Q3 | USD 677 k | Comprar |
4,214
+770
| +22% | +USD 118 k | 0.01% | 1064 |
|
|
2014
Q2 | USD 506 k | Vender |
3,444
-1,405
| -29% | -USD 195 k | 0.01% | 1235 |
|
|
2014
Q1 | USD 672 k | Vender |
4,849
-2,282
| -32% | -USD 343 k | 0.01% | 1026 |
|
|
2013
Q4 | USD 902 k | Vender |
7,131
-207
| -3% | -USD 21.4 k | 0.01% | 822 |
|
|
2013
Q3 | USD 675 k | Comprar |
7,338
+190
| +3% | +USD 15.3 k | 0.01% | 924 |
|
|
2013
Q2 | USD 491 k | Comprar |
+7,148
| Nuevas | +USD 437 k | 0.01% | 1031 |
|
Otros fondos que tienen JAZZ en su cartera
Posición de Commonwealth Equity Services en JAZZ: resumen de T2 2026
Commonwealth Equity Services redujo su participación en Jazz Pharmaceuticals (JAZZ) en 1.6% durante T2 2026, al vender acciones por un valor estimado de USD 42.1 k, y conservó 11,939 acciones valuadas en USD 2.88 M. La posición representa ﹤0.01% de la cartera y ocupa el puesto #1806.
Commonwealth Equity Services reportó por primera vez una posición en JAZZ en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. Al cierre de T2 2026, 649 fondos que sigue Wall St. Rank mantienen una posición en JAZZ.
- Al cierre de T2 2026, Commonwealth Equity Services tenía 11,939 acciones de Jazz Pharmaceuticals con un valor de USD 2.88 M.
- Commonwealth Equity Services vendió 192 acciones de Jazz Pharmaceuticals en T2 2026, por un valor estimado de USD 42.1 k.
- Jazz Pharmaceuticals representó ﹤0.01% de la cartera de Commonwealth Equity Services en T2 2026 y fue su posición número 1806.
- Commonwealth Equity Services reportó por primera vez una posición en Jazz Pharmaceuticals en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- Al cierre de T2 2026, 649 fondos que sigue Wall St. Rank tenían Jazz Pharmaceuticals en cartera.
Según el Informe 13F de Commonwealth Equity Services correspondiente a T2 2026, presentado el 29 jul 2026.